Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Wed, 5-Aug 4:01 PM ET)
BDTX Phase 2 Silevertinib Results Update Scheduled—Key Milestone Approaches for EGFRm NSCLC Therapy
Market Chameleon (Wed, 20-May 6:32 AM ET)
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Black Diamond Therapeutics trades on the NASDAQ stock market under the symbol BDTX.
As of September 22, 2026, BDTX stock price climbed to $1.98 with 683,787 million shares trading.
BDTX has a beta of 2.18, meaning it tends to be more sensitive to market movements. BDTX has a correlation of 0.15 to the broad based SPY ETF.
BDTX has a market cap of $113.43 million. This is considered a Micro Cap stock.
Last quarter Black Diamond Therapeutics reported $0 in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-30 million and exceeded earnings estimates by $.03.
In the last 3 years, BDTX traded as high as $7.66 and as low as $1.20.
The top ETF exchange traded funds that BDTX belongs to (by Net Assets): VTI, IWM, FESM, VXF, SMLF.
BDTX has underperformed the market in the last year with a price return of -39.6% while the SPY ETF gained +17.7%. However, in the short term, BDTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.3% vs +3.8% return in SPY. But in the last 2 weeks, BDTX shares have been beat by the market, returning -6.6% compared to an SPY return of +0.7%.
BDTX support price is $1.89 and resistance is $2.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDTX shares will trade within this expected range on the day.
